# Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray

> **NCT06461949** · PHASE3 · WITHDRAWN · sponsor: **National Institute on Deafness and Other Communication Disorders (NIDCD)**

## Conditions studied

- Allergic Fungal Rhinosinusitis (AFRS)
- Chronic Rhinosinusitis (CRS)
- Asthma
- Nasal Polyps

## Interventions

- **DRUG:** Dupilumab

## Key facts

- **NCT ID:** NCT06461949
- **Lead sponsor:** National Institute on Deafness and Other Communication Disorders (NIDCD)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-07-17
- **Primary completion:** 2024-07-17
- **Final completion:** 2024-07-17
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Closed by sponsor, lack of enrollment.
- **Last updated:** 2024-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06461949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06461949, "Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray". Retrieved via MORVS 2026-11-03 from https://api.morvs.ai/clinical/NCT06461949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*